Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis

2019 ◽  
Vol 46 (11) ◽  
pp. 2289-2297 ◽  
Author(s):  
Ali Afshar-Oromieh ◽  
Bernd Vollnberg ◽  
Ian Alberts ◽  
Alexandrine Bähler ◽  
Christos Sachpekidis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Multiparametric Mri ◽  
Recurrent Prostate Cancer ◽  
Psma Ligand ◽  
Pet Ct

Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer

2019 ◽  
Vol 103 (1) ◽  
pp. 95-104 ◽  
Author(s):  
Alexander Soldatov ◽  
Christoph A.J. von Klot ◽  
Daniel Walacides ◽  
Thorsten Derlin ◽  
Frank M. Bengel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Recurrent Prostate Cancer ◽  
Ct Guided ◽  
Psma Ligand ◽  
Pet Ct

scholarly journals Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

2013 ◽  
Vol 41 (1) ◽  
pp. 11-20 ◽  
Author(s):  
Ali Afshar-Oromieh ◽  
Christian M. Zechmann ◽  
Anna Malcher ◽  
Matthias Eder ◽  
Michael Eisenhut ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Recurrent Prostate Cancer ◽  
Psma Ligand ◽  
Pet Ct

scholarly journals Detection Rate of 68Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy

Biomedicines ◽  
2020 ◽  
Vol 8 (11) ◽  
pp. 511
Author(s):  
Joachim Brumberg ◽  
Melanie Beckl ◽  
Alexander Dierks ◽  
Andreas Schirbel ◽  
Markus Krebs ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Detection Rate ◽  
Androgen Deprivation ◽  
Disease Stage ◽  
Whole Body ◽  
Recurrent Prostate Cancer ◽  
Detection Rates ◽  
Psma Ligand ◽  
Pet Ct

Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the detection rate of 68Ga-PSMA ligand PET/CT. Thus, 399 patients with initial radical prostatectomy and 68Ga-PSMA ligand PET/CT during PSA relapse were retrospectively evaluated. Propensity score matching was used to create two balanced groups of 62 subjects who either did or did not receive ADT within six months before imaging. All 68Ga-PSMA ligand PET/CT were evaluated visually and with semiquantitative measures. The detection rate of tumor recurrence was significantly higher in the group with ADT (88.7% vs. 72.6%, p = 0.02) and improved with increasing PSA-levels in both groups. In subjects with pathological PET/CT and ADT, whole-body total lesion PSMA (p < 0.01) and PSMA-derived tumor volume (p < 0.01) were significantly higher than in those without ADT. More PSMA-positive lesions and higher PSMA-derived volumetric parameters in patients with ADT suggest that a better detection rate is related to a (biologically) more advanced disease stage. Due to high detection rates in patients with PSA-levels < 2 ng/mL, the withdrawal of ADT before PSMA ligand PET/CT cannot be recommended.

The role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer

2021 ◽  
Author(s):  
Dominic Bagguley ◽  
Sean Ong ◽  
James P Buteau ◽  
Sam Koschel ◽  
Nattakorn Dhiantravan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Imaging Technique ◽  
Imaging Techniques ◽  
Multiparametric Mri ◽  
Prostate Specific Membrane Antigen ◽  
Recurrent Prostate Cancer ◽  
Psma Pet ◽  
Pet Ct ◽  
Specific Membrane

Prostate-specific membrane antigen (PSMA) PET/CT is a novel imaging technique for the detection and staging of either primary or recurrent prostate cancer. Early studies demonstrated its improved sensitivity and specificity over and in combination with other currently employed imaging techniques, such as multiparametric MRI, bone scan, PET and CT. However, the lack of strength and confidence in these studies has meant incorporation of PSMA PET/CT into clinical guidelines and practice has been limited to date. In response, a number of high-quality prospective studies have recently emerged and reflect exciting results seen in preceding publications. Here we recount some of the key earlier publications, report results from the latest studies and look to the future discussing some of the eagerly awaited ongoing clinical trials.

MP53-08 THE DIAGNOSTIC VALUE OF 68 GA-LABELLED PSMA-LIGAND PET/CT IN MEN WITH RECURRENT PROSTATE CANCER

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Boris Hadaschik ◽  
Ali Afshar-Oromieh ◽  
Jan Radtke ◽  
Silvan Boxler ◽  
Matthias Eder ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Value ◽  
Recurrent Prostate Cancer ◽  
Psma Ligand ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document